FMP
NASDAQ
0.581 USD
-0.0076 (-1.31%)
Mr. David M. Maggio
Healthcare
Biotechnology
https://www.metacrine.com
NASDAQ
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
0001634379
US59101E1038
59101E103
3985 Sorrento Valley Boulevard
858 369 7800
US
10
Sep 16, 2020